The LC rate was
99% at 1 and 2 years. The 1 and 2-year OS were 81.8% and 56.6% respectively. The median time to progression
was 9 months (0–38). The rate of hepatic toxicity was 7.7% [1.6–13.7], 14.9% [5.7–23.2] and 23.1% [9.9–34.3]
at 6 months, 1 year and 2 years respectively. In multivariate analysis, female gender (HR 7.87 [3.14–19.69]), a
BCLC B-C stage (HR 3.71 [1.41–9.76]), a sum of all lesion diameters P2 cm (HR 7.48 [2.09–26.83]) and a
previous treatment (HR 0.10 [0.01–0.79]) were independent prognostic factors of overall survival.
Conclusion: SBRT allows high local control for inoperable hepatocellular carcinomas. It should be
considered when an ablative treatment is indicated in Child A patients